Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| DSIP (Delta Sleep-Inducing Peptide) | KPV | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 100-300 mcg administered before bedtime via subcutaneous injection or intranasal. | Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation. |
| Timing | 30-60 minutes before desired sleep onset. Evening only. | Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous. |
| Cycle Duration | 2-4 week cycles with equal rest periods to prevent tolerance. | 4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
DSIP is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from rabbit brain hypothalamus in 1977. It modulates GABAergic neurotransmission by potentiating GABA-activated currents in hippocampal and cerebellar neurons while blocking NMDA-activated potentiation in cortical neurons. It also interacts with opioid-associated receptors, modulates serotonin and dopamine systems (increasing serotonin levels), and promotes delta wave (slow-wave) sleep through mechanisms that remain incompletely characterized.
Research indicates 100-300 mcg administered before bedtime via subcutaneous injection or intranasal.
30-60 minutes before desired sleep onset. Evening only.
2-4 week cycles with equal rest periods to prevent tolerance.
KPV (Lysine-Proline-Valine) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) that inhibits NF-kB signaling through a non-melanocortin receptor-mediated mechanism. It is transported intracellularly via the PepT1 transporter, where it stabilizes IkB-alpha and suppresses nuclear translocation of p65RelA by competing with importin-beta at the armadillo domain 7 and 8 binding site. It also reduces MAPK inflammatory signaling and IL-8 secretion in intestinal epithelial cells.
Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation.
Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous.
4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision.
Fast buy links (we may earn a small commission at no extra cost).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →